Know Cancer

or
forgot password

    • cancer clinical trials in middletown, OH

    • A Study to Evaluate Tarceva in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
    Signal Point Hematology/Oncology, Inc.
    Middletown, Ohio 45042
    Lung Cancer, Non-small-cell Lung Carcinoma
    S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
    Middletown Regional Hospital
    Middletown, Ohio 45044
    Esophageal Cancer
    Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
    Middletown Regional Hospital
    Middletown, Ohio 45044
    Esophageal Cancer
    S0414 Cetuximab, Combo Chemo, and RT in Locally Advanced Esophageal Cancer
    Middletown Regional Hospital
    Middletown, Ohio 45044
    Esophageal Cancer
    ABI-007 (Nab-Paclitaxel) and Gemcitabine in Treating Women With Metastatic Breast Cancer
    Middletown Regional Hospital
    Middletown, Ohio 45044
    Breast Cancer
    S0408: Capecitabine, Oxaliplatin, and Bevacizumab in Pts Undergoing Surgery for Liver Mets From Colorectal Cancer
    Middletown Regional Hospital
    Middletown, Ohio 45044
    Colorectal Cancer, Metastatic Cancer
    Cetuximab and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer
    Middletown Regional Hospital
    Middletown, Ohio 45044
    Lung Cancer
    Lenalidomide (Revlimid®, CC-5013) in Subjects With Relapsed or Refractory Indolent Non-Hodgkin’s Lymphoma
    Signal Point Hematology/Oncology
    Middletown, Ohio 45042
    Non-Hodgkins Lymphoma
    S0505 Sorafenib in Treating Patients With Advanced Soft Tissue Sarcomas
    Middletown Regional Hospital
    Middletown, Ohio 45044
    Sarcoma
    S0509: AZD2171 in Treating Patients With Malignant Pleural Mesothelioma That Cannot Be Removed By Surgery
    Middletown Regional Hospital
    Middletown, Ohio 45044
    Malignant Mesothelioma
    A Survival Study for Women With Advanced Lung Cancer Who Have Not Previously Received Chemotherapy.
    Signal Point Hematology/Oncology, Inc.
    Middletown, Ohio 45042
    NSCLC
    S0437 Long-Term Follow-Up of Patients Who Were Diagnosed With Prostate Cancer on PCPT
    Middletown Regional Hospital
    Middletown, Ohio 45044
    Prostate Cancer
    Pyridoxine and Topical Urea/Lactic Acid-Based Cream in Preventing Hand-Foot Syndrome in Patients Receiving Capecitabine for Breast Cancer or Other Cancer
    Middletown Regional Hospital
    Middletown, Ohio 45044
    Breast Cancer, Drug/Agent Toxicity by Tissue/Organ, Unspecified Adult Solid Tumor, Protocol Specific
    S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
    Middletown Regional Hospital
    Middletown, Ohio 45044
    Head and Neck Cancer
    APF530 or Palonosetron Combined With Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer
    Signal Point Hematology Oncology Incorporated
    Middletown, Ohio 45042
    Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific
    Topical Sunscreen in Preventing Skin Rash in Patients Receiving Drugs Such as Erlotinib or Cetuximab for Cancer
    Middletown Regional Hospital
    Middletown, Ohio 45044
    Dermatologic Complications, Unspecified Adult Solid Tumor, Protocol Specific
    Citalopram in Treating Postmenopausal Women With Hot Flashes
    Middletown Regional Hospital
    Middletown, Ohio 45044
    Breast Cancer, Hot Flashes, Psychosocial Effects of Cancer and Its Treatment
    Methylphenidate in Treating Patients With Fatigue Caused by Cancer
    Middletown Regional Hospital
    Middletown, Ohio 45044
    Fatigue, Unspecified Adult Solid Tumor, Protocol Specific
    Carboplatin and ABI-007 in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery
    Middletown Regional Hospital
    Middletown, Ohio 45044
    Melanoma (Skin)
    Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
    Middletown Regional Hospital
    Middletown, Ohio 45044
    Breast Cancer
    Study of GTx-024 on Muscle Wasting (Cachexia) Cancer.
    Signal Point Clinical Research Center, LLC
    Middletown, Ohio 45042
    Cachexia
    INNO-206 in Patients With Small Cell Lung Cancer (SCLC)
    Signal Point Hematology/Oncology, Inc.
    Middletown, Ohio 45042
    Small Cell Lung Cancer
    Safety and Efficacy Study of GCSF Therapy to Treat Patients at High Risk for Chemotherapy Induced Severe Neutropenia
    Signal Point Clinical Research Center, LLC
    Middletown, Ohio 45042
    Breast Cancer, Neutropenia
    Study of XL647 in Subjects With NSCLC Who Have Progressed After Responding to Treatment With Gefitinib or Erlotinib
    Signal Point Clinical Research Center
    Middletown, Ohio 45042
    Carcinoma, Non-Small-Cell Lung
    Phase II Study to Evaluate Efficacy and Safety of RP101 in Combination With Gemcitabine
    Signal Point Clinical Research Center, LLC
    Middletown, Ohio 45042
    Pancreatic Cancer
    Study of Pralatrexate vs. Erlotinib for Non-Small Cell Lung Cancer After at Least 1 Prior Platinum-based Treatment
    Signal Point Clinical Research Center
    Middletown, Ohio 45042
    Non-small Cell Lung Cancer
    Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme
    Middletown Regional Hospital
    Middletown, Ohio 45044
    Brain and Central Nervous System Tumors
    A Bioequivalence Study of Docetaxel for Injectable Emulsion (ANX-514) in Patients With Advanced Cancer
    Signal Point Hematology/Oncology Inc.
    Middletown, Ohio 45042
    Advanced Cancer
    Evaluation of AVE5026 in the Prevention of Venous Thromboembolism in Cancer Patients Undergoing Chemotherapy
    Investigational Site Number 840003
    Middletown, Ohio 45042
    Venous Thromboembolism, Cancer
    Safety and Efficacy of Talactoferrin in Previously Treated Patients With Non-small Cell Lung Cancer
    Signal Point Clinical Research Center
    Middletown, Ohio 45042
    Non Small Cell Lung Cancer
    A Study of ASA404 or Placebo in Combination With Docetaxel in Second-line Treatment for (Stage IIIb/IV) Non-small Cell Lung Cancer
    Signal Point Hematology/Oncology, Inc.
    Middletown, Ohio 45042
    Non-Small Cell Lung Cancer
    An Efficacy and Safety Study of MORAb-003 in Platinum-Resistant or Refractory Relapsed Ovarian Cancer
    Signal Point Clinical Research Center
    Middletown, Ohio 45042
    Ovarian Cancer
    Study of Carboplatin/Paclitaxel With or Without Investigational Drug (CS-7017) in Subjects With Metastatic Non-small Cell Lung Cancer
    Signal Point Clinical Research Center
    Middletown, Ohio 45042
    Metastatic Non-small Cell Lung Cancer
    Capecitabine With or Without Sunitinib Malate as First-Line Therapy in Treating Patients With Metastatic Cancer of the Esophagus or Gastroesophageal Junction
    Middletown Regional Hospital
    Middletown, Ohio 45044
    Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer
    S0309, Collecting and Storing Blood and Bone Marrow Samples From Patients With Myeloma, Waldenstrom's Macroglobulinemia, Amyloidosis, or Monoclonal Gammopathy of Undetermined Significance
    Middletown Regional Hospital
    Middletown, Ohio 45044
    Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Precancerous Condition
    S9910, Collecting and Storing Blood and Bone Marrow Samples From Patients With Hematologic Cancer
    Middletown Regional Hospital
    Middletown, Ohio 45044
    Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
    Docetaxel, Oxaliplatin, Capecitabine, Fluorouracil, and Radiation Therapy in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction
    Middletown Regional Hospital
    Middletown, Ohio 45044
    Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer, Gastric Cancer
    S9007, Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
    Middletown Regional Hospital
    Middletown, Ohio 45044
    Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
    S0916, MLN1202 in Treating Patients With Bone Metastases
    Middletown Regional Hospital
    Middletown, Ohio 45044
    Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
    A Multicenter, Open-Label, Single-Arm Evaluation of Palonosetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Subjects Who Have Experienced CINV(Chemotherapy-Induced Nausea and Vomiting) During the Previous Cycle of Low Emetogenic Chemotherapy (LEC)
    Signal Point Clinical Research
    Middletown, Ohio 45042
    Patients With Confirmed Malignant Disease to Receive Low Emetogenic Chemotherapy (LEC) or Who Experienced at Least Nausea and Vomiting During Last Cycle of LEC
    Pixantrone Dimaleate in Treating Patients With HER2-Negative Metastatic Breast Cancer
    Middletown Regional Hospital
    Middletown, Ohio 45044
    Breast Cancer
    Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder Cancer
    Signal Point Clinical Research Center, LLC
    Middletown, Ohio 45042
    Bladder Neoplasm, Intravesical Drug Administration, Neoplasm Recurrence, Local, Transitional Cell, Carcinoma, Carcinoma in Situ, Mycobacterium
    An Efficacy and Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting
    Signal Point Clinical Research Center
    Middletown, Ohio 45042
    Chemotherapy-Induced Nausea and Vomiting
    An Efficacy and Safety Study of Oral and Intravenous Palonosetron for the Prevention of Nausea and Vomiting
    Signal Point Hematolgy Oncology, Inc.
    Middletown, Ohio 45042
    Chemotherapy-Induced Nausea and Vomiting